A Phase 1 Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2016
At a glance
- Drugs E 6007 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Co Ltd
- 19 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 11 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 May 2015, according to ClinicalTrials.gov record.
- 11 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2015, according to ClinicalTrials.gov record.